Table 2. Rectal Tumor and Neoadjuvant Therapy Characteristics of Patients in the MOABP and MBP Plus Placebo Groups.
| Characteristic | No. (%)a | |
|---|---|---|
| MBP plus placebo (n = 288) | MOABP (n = 277) | |
| Benign tumor | 27 (9.4) | 27 (9.7) |
| Rectal cancer TNM classification | ||
| No. of patientsb | 261 | 250 |
| T0/Tx | 7 (2.7) | 8 (3.2) |
| T1-T2 | 58 (22.4) | 59 (23.7) |
| T3 | 131 (50.6) | 114 (45.8) |
| T4 | 63 (24.3)c | 68 (27.3)d |
| N0 | 114 (44.0) | 97 (38.8) |
| N1 | 91 (35.1) | 98 (38.2) |
| N2 | 54 (20.8)e | 55 (22.0) |
| M0 | 248 (95.0) | 238 (95.2) |
| M1 | 13 (5.0) | 12 (4.8) |
| Rectal cancer stage | ||
| No. of patientsb | 261 | 250 |
| 1 | 53 (20.5) | 53 (21.2) |
| 2 | 59 (22.8) | 45 (18.0) |
| 3 | 134 (51.7) | 140 (56.0) |
| 4 | 13 (5.0)f | 12 (4.8) |
| Tumor height at endoscopy, median (IQR), cm | 10.0 (7.0-12.0)g | 10.0 (7.0-12.0)h |
| Tumor height at MRI, median (IQR), cm | 8.35 (6.5-10.5)i | 8.5 (6.5-10.0)j |
| Neoadjuvant treatment | ||
| None | 167 (64.0) | 162 (65.7) |
| Short-course radiotherapy | 39 (14.9) | 32 (12.8) |
| Short-course radiotherapy with long waiting time | 2 (0.8) | 5 (2.0) |
| Long-course chemoradiotherapy | 50 (19.2) | 46 (18.4) |
| Short-course radiotherapy and chemotherapy | 1 (0.4) | 2 (0.8) |
| Chemotherapy only | 2 (0.8) | 3 (1.2) |
Abbreviations: TNM, tumor, nodes, and metastases; MBP, mechanical bowel preparation; MOABP, mechanical and oral antibiotics bowel preparation; MRI, magnetic resonance imaging.
a
Patients with missing data for each variable were not included in calculations. Some TNM and tumor height in MRI data are missing because MRI was not taken, or tumor was not visible during MRI.
b
Based on preoperative computed tomography (M category) and MRI (T and N categories).
c
Data missing for 2 patients.
d
Data missing for 1 patient.
e
Data missing for 2 patients.
f
Data missing for 2 patients.
g
Data missing for 7 patients.
h
Data missing for 4 patients.
i
Data missing for 8 patients.
j
Data missing for 9 patients.